On January 27, 2026, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. announced that its wholly owned subsidiary, Xiamen Innovax Biotech Co., Ltd. (“Innovax”), has maintained compliance with the World Health Organization (WHO) Prequalification (PQ) standards following a periodic re-inspection conducted by the WHO Prequalification Inspection Team (WHO PQT–INS) of its bivalent HPV vaccine, Cecolin. The vaccine was initially prequalified by WHO in 2021, and this re-inspection reaffirms its continued compliance with international quality standards.

At Xiamen Innovax, women are playing a leading role in advancing vaccine innovation and expanding access to cervical cancer prevention. This commitment was recently recognized when the company received the National March 8th Red-Banner Collective, a national honor awarded by the All-China Women's Federation to organizations demonstrating outstanding contributions by women. The recognition highlights the important role women play across Xiamen Innovax’s research, manufacturing, and quality teams—and their contributions to the development of innovative HPV vaccines designed to protect women’s health.

Thailand, Dec. 4, 2025 — Xiamen Innovax Biotech Co., Ltd. (INNOVAX) and Thailand’s National Vaccine Institute (NVI) jointly served as witnesses to Global Biotech Products Co., Ltd. (GBP) being awarded the Thailand Triple S Awards 2025 (Science, Society and Sustainability) by the Thailand Science Research and Innovation Agency (TSRI), an honor unveiled as part of the Thailand SRI Index 2025. This milestone recognizes the joint efforts of INNOVAX and GBP in the 9-valent HPV vaccine technology-transfer project, with strong support from NVI.

November 14-16, 2025 - The CAV First Annual Academic Conference & Expo (CAVAC) was successfully held in Xiamen, Fujian.

On October 23, 2025, Dr. Zhiming (Tiffany) Jiang, General Manager of Wantai Group, and Dr. Huirong (Harry) Pan, General Manager of Xiamen Innovax Biotech Co., Ltd. (“Innovax”), participated in the 37th International Papillomavirus Society (IPVS) Conference in Bangkok, Thailand. They chaired a dedicated symposium titled “A New Era of HPV Vaccines: The Efforts from Developing Country Manufacturers for Global Cervical Cancer Elimination,” which sparked lively discussions among attending experts and scholars. Meanwhile, under the theme “Together Against HPV,” Innovax’s booth (#09) also attracted active engagement.

Xiamen Innovax Biotech Co., Ltd. (Innovax) today announced its participation in the 37th International Papillomavirus Conference (IPVS 2025), taking place from October 23 to 26, 2025, in Bangkok, Thailand. In addition to hosting Booth 9, Innovax will present in a symposium—for the first time to the global academic community—the 34-month Phase III clinical data for the world's second HPV 9-valent vaccine, Cecolin 9, along with its localization strategy and implementation in Thailand.